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Background: The cardio ankle vascular index (CAVI) is a new index of the overall stiffness of the artery from the
origin of the aorta to the ankle. This index can estimate the risk of atherosclerosis. We aimed to find the relationship
between CAVI and target organ damage (TOD), vascular structure and function, and cardiovascular risk factors in
Caucasian patients with type 2 diabetes mellitus or metabolic syndrome.
Methods: We included 110 subjects from the LOD-Diabetes study, whose mean age was 61 ± 11 years, and 37.3% were
women. Measurements of CAVI, brachial ankle pulse wave velocity (ba-PWV), and ankle brachial index (ABI) were taken
using the VaSera device. Cardiovascular risk factors, renal function by creatinine, glomerular filtration rate, and albumin
creatinine index were also obtained, as well as cardiac TOD with ECG and vascular TOD and carotid intima media thick-
ness (IMT), carotid femoral PWV (cf-PWV), and the central and peripheral augmentation index (CAIx and PAIx). The
Framingham-D’Agostino scale was used to measure cardiovascular risk.
Results: Mean CAVI was 8.7 ± 1.3. More than half (54%) of the participants showed one or more TOD (10% cardiac, 13%
renal; 48% vascular), and 13% had ba-PWV≥ 17.5 m/s. Patients with any TOD had the highest CAVI values: 1.15 (CI 95%
0.70 to 1.61, p < 0.001) and 1.14 (CI 95% 0.68 to 1.60, p < 0.001) when vascular TOD was presented, and 1.30 (CI 95%
0.51 to 2.10, p = 0.002) for the cardiac TOD. The CAVI values had a positive correlation with HbA1c and systolic and
diastolic blood pressure, and a negative correlation with waist circumference and body mass index. The positive
correlations of CAVI with IMT (β = 0.29; p < 0.01), cf-PWV (β = 0.83; p < 0.01), ba-PWV (β = 2.12; p < 0.01), CAIx (β = 3.42;
p < 0.01), and PAIx (β = 5.05; p = 0.04) remained after adjustment for cardiovascular risk, body mass index, and
antihypertensive, lipid-lowering, and antidiabetic drugs.
Conclusions: The results of this study suggest that the CAVI is positively associated with IMT, cf-PWV, ba-PWV,
CAIx, and PAIx, regardless of cardiovascular risk and the drug treatment used. Patients with cardiovascular TOD
have higher values of CAVI.
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The early detection of atherosclerosis is important for
patients with type 2 diabetes mellitus (T2DM) or meta-
bolic syndrome [1], because cardiovascular disease is a
main cause of death in these people [2,3].These patholo-
gies are associated with more cardiovascular risk factors
[4,5], more comorbidities [6,7], and more renal [8], cardiac
[9,10], and vascular [11] target organ damage (TOD). They
are also associated with premature vascular aging and
altered parameters assessing vascular structure, such as
the ankle brachial index (ABI) [12] or carotid intima
media thickness (IMT) [11]. They also occur with in-
creased arterial stiffness [13] based on carotid femoral
pulse wave velocity (cf-PWV), or with high brachial-
ankle pulse wave velocity (ba-PWV) could predict
all-cause mortality and cardiovascular events in subjects
with diabetes [14,15], increased ba-PWV was signifi-
cantly correlated with cardiac autonomic neuropathy
and with subclinical myocardial injury in patients with
type 2 diabetes [16].They are also associated with pulse
wave parameters such as the central and peripheral
augmentation indices (CAIX and PAIx) [17-19].
The cardio-ankle vascular index (CAVI) is a new index
[20,21] of the overall stiffness of the artery from the origin
of the aorta to the ankle, and it is able to estimate the risk
of atherosclerosis [22]. The arterial stiffness estimated
using CAVI in healthy subjects increases linearly with
aging, and is higher in men than in women [23]. In pa-
tients with risk factors such as diabetes or obesity [24-26],
the CAVI values are higher than in controls. CAVI is asso-
ciated with carotid and coronary atherosclerosis [27-29].
The CAVI method is a useful tool to screen people with
moderate to advanced levels of atherosclerosis [30].
Even though there is much evidence supporting the
relationship between CAVI and cardiovascular risk factors
and atherosclerosis, most studies have been done on Asian
populations. The clinical relevance of this work is given
because it is the first study to analyze in the same sample,
the association between CAVI and cardiovascular risk
factors, TOD (renal, vascular, and heart), other parameters
of vascular structure and function, and the thickness of
the retinal vessels in Caucasian patients with increased
insulin resistance. Therefore, the aim of this study is to
analyze the association of CAVI with target organ damage,
vascular structure and function, and cardiovascular risk
factors in Caucasian patients with T2DM or metabolic
syndrome.Methods
Study design
This study analyzed 110 subjects in the 4th year of
follow up who were included in the longitudinal LOD-
DIABETES study (NCT01065155) [31].
Study population
Using consecutive sampling, we included 112 patients
who visited their family doctor from January 2009 to
January 2010 with T2DM (n = 68), which was defined
using the American Diabetes Association criteria [32]
or metabolic syndrome (n = 44) (defined according to
the National Cholesterol Education Program, ATP III1
definition [33]). The subjects were sampled from a
population of 46000 people from two primary care
centers (including 2412 diagnosed with diabetes and
4100 with metabolic syndrome). The exclusion criteria
were patients unable to comply with the protocol re-
quirements (psychological and/or cognitive disorders,
failure to cooperate, educational limitations, problems
with understanding written language, failure to sign the
informed consent document), patients participating or
planning to participate in a clinical trial during the
study, and patients with serious comorbidities repre-
senting a threat to life over the subsequent 12 months.
Patients with a history of cardiovascular disease were
not excluded from the study. A sample-size calculation
indicated that the 110 patients included in the study
constituted a sufficient sample for detecting a correl-
ation coefficient of 0.26 between CAVI and IMT in a
two-sided test, with a significance level of 95% and
power of 80% (EPIDAT 4.0). The study was approved by
an independent ethics committee of Salamanca University
Hospital (Spain), and all participants gave written in-
formed consent according to the general recommenda-
tions of the Declaration of Helsinki [34].
Measurements
A detailed description has been published elsewhere
regarding how the clinical data were collected, the
anthropometric measurements were made, blood pres-
sure was recorded, TOD was assessed, and the analytical
parameters were obtained [31].
Office blood pressure
Office blood pressure (BP) was calculated as the average
of the last two of three measurements of systolic blood
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with a validated sphygmomanometer (OMRON Model
M10-IT). Measurements were made on the dominant
arm of participants in the seated position after at least
5 minutes of rest, with a cuff of appropriate size as
determined by measurement of the upper-arm circum-
ference and following the recommendations of the
European Society of Hypertension [35].
Vascular assessment
Cardio ankle vascular index (CAVI), brachial ankle pulse
wave velocity (ba-PWV), and ankle/brachial index (ABI)
were measured using a VaSera VS-1500® device (Fukuda
Denshi). The ba-PWV was calculated, as was CAVI, which
gives a more accurate calculation of the degree of athero-
sclerosis. CAVI integrates the cardiovascular elasticity
derived from the aorta to the ankle pulse velocity through
an oscillometric method, it is used as a good measure of
vascular stiffness, and it does not depend on BP [21].
CAVI values were automatically calculated by substituting
the stiffness parameter β in the following equation to
detect the vascular elasticity and the brachial ankle PWV:
Stiffness parameter β = 2ρ × 1/ (Ps –Pd) × ln (Ps/Pd) ×
ba-PWV2, where ρ is the blood density, Ps and Pd are SBP
and DBP in mmHg, respectively, and the ba-PWV is mea-
sured between the aortic valve and the ankle. The average
coefficient of the variation of the CAVI is less than 5%,
which is small enough for clinical use and confirms that
CAVI has favorable reproducibility [20,23]. CAVI was
measured at rest and considered normal (CAVI < 8),
borderline (8 ≤ CAVI < 9), or abnormal with subclinical
atherosclerosis (CAVI ≥9). ba-PWV ≥ 17.5 was consid-
ered abnormal [36,37]. The higher obtained CAVIs and
ba-PWV were considered for the study.
Carotid femoral pulse wave velocity (cf-PWV) and
peripheral (PAIx) and central augmentation index (CAIx)
These parameters were estimated using the SphygmoCor
System (AtCor Medica lPty Ltd., Head Office, West
Ryde, Australia). The central augmentation index (CAIx)
is a composite index that integrates the amount of the
wave that is reflected back to the aorta depending on
the tone of the resistance arteries, which are the main
peripheral reflecting sites. This system (Px Pulse Wave
Analysis) was used with the patient in the sitting
position and resting the arm on a rigid surface. Pulse
wave analysis was performed with a sensor in the radial
artery using mathematical transformation to estimate
the aortic pulse wave. The reliability of these measure-
ments was evaluated before the study using the CAIx
intra-class correlation coefficient (ICC), which showed
values of 0.97 (95% CI: 0.94-0.99) for intra-observer
agreement in repeated measurements of 22 subjects.
According to the Bland-Altman analysis, the meandifference for intraobserver agreement (95% limits of
agreement) was 0.45 (−9.88-10.79). From the morph-
ology of the aortic wave, CAIx was estimated using the
following formula: increase in central pressure × 100/
pulse pressure. The value was adjusted to a heart rate of
75 by the SphygmoCor System device.
The peripheral augmentation index (PAIx) is a meas-
urement taken directly from the late systolic shoulder of
the peripheral arterial waveform. The index is defined
as the ratio of the difference in amplitude between the
second peak and diastolic pressure to the difference be-
tween the first peak and diastolic pressure [18]. The PAIx
was calculated to yield a percent (%) value as follows:
(second peak systolic blood pressure [SBP2] - diastolic
blood pressure [DBP])/(first peak SBP - DBP) × 100
[18]. The pulse waves of the carotid and femoral arteries
were analyzed using the SphygmoCor System with the
patient in a supine position. The delay was estimated
with respect to the ECG wave and calculating PWV.
Distance measurements were taken with a measuring
tape from the sternal notch to the carotid and femoral
arteries at the sensor location [35]. Subclinical organ
damage was defined as cf-PWV >12 m/s [35].
Assessment of vascular structure by carotid intima media
thickness (IMT)
Carotid ultrasound to assess carotid IMT was performed
by two investigators trained for this purpose before starting
the study. The reliability of the recordings was evaluated
before the study using the intra-class correlation coeffi-
cient, which showed values of 0.97 (95% CI: 0.94 to 0.99)
for intra-observer agreement in repeated measurements on
20 subjects, and 0.90 (95% CI: 0.74 to 0.96) for inter-
observer agreement. According to the Bland-Altman
analysis, the mean difference for interobserver agree-
ment (95% limits of agreement) was 0.01 (−0.03 to
0.06). A Sonosite Micromax ultrasound device paired
with a 5–10 MHz multi-frequency high-resolution linear
transducer with Sonocal software was used for performing
automatic measurements of IMT in order to optimize
reproducibility.
Measurements were made of the common carotid
after the examination of a 10-mm longitudinal section
at a distance of 1 cm from the bifurcation. They were
performed in the anterior or proximal wall and in the
posterior or distal wall in the lateral, anterior, and
posterior projections. The measurements were taken
following an axis perpendicular to the artery to discrim-
inate two lines: one for the intima-blood interface and
the other for the media-adventitious interface. A total
of 6 measurements were obtained of the right carotid,
with another 6 measurements of the left carotid. Average
values (average IMT) automatically calculated by the
software were used [38]. The measurements were
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extended and slightly turned opposite to the examined
carotid artery. Average IMT was considered abnormal
if > 0.90 mm, if there were atherosclerotic plaques with
a diameter of 1.5 mm, or if there was a focal increase of
0.5 mm or 50% of the adjacent IMT [35].Evaluation of retinal vessels
Retinography was performed using a Topcon TRC NW
200 non-mydriatic retinal camera (Topcon Europe B.C.,
Capelle a/d Ijssel, The Netherlands). Nasal and temporal
images centered on the disk were obtained. The nasal
image with the centered disk was loaded into developed
software called the arteriolar-venular (AV) diameters
index calculator (Ciclorisk SL, Salamanca, Spain, registry
no. 00/2011/589). The software automatically recognizes
the disk and draws two external concentric circles which
delimit area A, which is between 0 and 0.5 disk diameters
from the optic disk margin, and area B, which is between
0.5 and 1 disk diameters from the margin.
The software first identifies the limits of the different
vessels and then automatically recognizes arteries and
veins. Then, it makes multiple measurements of the
diameter of the section of the vessels circulating through
area B. It finally estimates the mean caliber of veins and
arteries in mm, and these measurements are summa-
rized as an arteriole-venule ratio (AVR). An AVR of 1.0
suggests that arteriolar diameters are the same on aver-
age as venular diameters in the eye, whereas a smaller
AVR suggests narrower arterioles [39].
We used pairs of the main vessels in the upper and
lower temporal quadrants, rejecting all other vessels, to
improve reliability and increase efficiency of the process.
Measures are analyzed for each quadrant separately
and together to estimate the mean measure in each eye.
The reliability of such recordings was evaluated before
the study using the ICC, which showed values of 0.998
(95% CI: 0.997 to 0.999) for vein caliber, 0.969 (95% CI
0.940–0.984) for arteries, and 0.981 (95% CI 0.965–
0.990) for AVR intraobserver ICC, which was measured
using a subsample of 40 photographs. The estimated
average time to analyze a patient (two photographs)
was less than 2 min [40].Renal assessment
Kidney damage was assessed by measuring plasma cre-
atinine concentration. Glomerular filtration rate (GFR)
was estimated according to the Modification of Diet
in Renal Disease-Isotopic Dilution Mass Spectrometry
(MDRD-IDMS) [41], and proteinuria was assessed from
the albumin/creatinine ratio. TOD was defined according
to the criteria in the 2007 European Society of Hyper-
tension/European Society of Cardiology Guidelines [42].Cardiac assessment
The electrocardiographic examination was performed
using a General Electric MAC 3.500 ECG System (General
Electric, Niskayuna, NY, USA), which automatically
measures the voltage and duration of waves and estimates
the criteria of the Sokolow and Cornell voltage-duration
product (Cornell VDP). TOD was defined according to
criteria in the 2007 European Society of Hypertension/
European Society of Cardiology Guidelines [42].
Cardiovascular risk assessment
Risk of cardiovascular morbidity and mortality was esti-
mated using the published Framingham-D’Agostino risk
equation [43]. Risk factors for morbidity and mortality
used by the Framingham-D’Agostino scale include age,
total cholesterol, high-density lipoprotein cholesterol,
and SBP as quantitative variables. Sex, drug treatment
for hypertension, smoking, and history of diabetes melli-
tus are dichotomous variables. We considered patients
to be at high risk when the scale was ≥20% for the next
10 years. The individuals performing the different tests
were blinded to the clinical data of the patients. All
assessments were made within a period of 10 days.
Statistical analysis
Continuous variables were expressed as the mean ±
standard deviation for normally distributed continuous
data, the median (interquartile range, IQR) for asymmet-
rically distributed continuous data, and the frequency
distribution for categorical data. Statistical normality was
tested using the Kolmogorov–Smirnov test. Quantitative
variables were compared using the Student t-test or
Mann–Whitney U-test as appropriate. A partial correl-
ation was examined between CAVI with cardiovascular
risk factors and target organ damage, controlling for
age, gender, and antihypertensive, lipid-lowering, and
antidiabetic drugs. We performed multiple linear re-
gression analyses with CAVI as the independent variable
and IMT mean, CAIx, PAIx, AVR, cf-PWV, and ba-PWV
as dependent variables. We adjusted by Framingham-
D’Agostino cardiovascular risk, body mass index (BMI),
and antihypertensive, lipid-lowering, and antidiabetic
drugs. The data were analyzed using the Statistical
Package for the Social Sciences version 20.0 (SPSS,
Chicago, IL, USA). A value of p < 0.05 was considered
statistically significant.
Results
Throughout the fourth year of study of follow-up, two
males died as a result of acute myocardial infarction:
one with T2DM and the other with metabolic syndrome
(aged 76 and 65 years, respectively).
Table 1 shows the demographics and clinical charac-
teristics, cardiovascular risk factors, and cardiovascular





Age (years) 61.2 11.1
Female sex n (%) 41 37.3
Smoking n (%) 19 17.6
Ischemic heart disease n (%) 11 10
Cerebrovascular disease n (%) 3 3.9
Waist circumference (cm) 102.9 11.9
Body mass index (kg/m2) 30.2 4.8
Obesity n (%) 55 50.9
Office systolic blood pressure (mmHg) 132 16
Office diastolic blood pressure (mmHg) 77 10
Office pulse pressure (mmHg) 56 15
Heart rate (beats/min) 68 11
Hypertension n (%) 90 81.8
Antihypertensive drugs n (%) 88 81.5
Serum glucose (mg/dL) 103 89.3-128.3
HbA1c (%) 6.3 5.7-7.0
Diabetes n (%) 71 64.5
Antidiabetic drugs n (%) 65 60.2
Total cholesterol (mg/dL) 185.3 31.9







Dyslipidemia n (%) 68 63.6
Metabolic syndrome n (%) 39 35.5




Values are means and standard deviations (SD) for normally distributed
continuous data, medians and interquartile range (IQR) for asymmetrically
distributed continuous data and absolute frequency and proportions for
categorical data.
Table 2 Values of organ damage markers and vascular




Serum creatinine (mg/dL) 0.9 0.7-1




Target organ damage (GFR <60) n (%) 6 5.6




Target organ damage renal n (%) 14 13.1
Cornell VDP (mmms) 1604.1 645.3
Sokolow (mm) 20.1 6.4
Target organ damage heart n (%) 11 10.3
Ankle/brachial index 1.14 0.11
Target organ damage ankle/





Target organ damage Carotid n (%) 36 33.6
cf-PWV (m/sec) 9.6 2.6
Target organ damage Pulse
Wave Velocity n (%)
30 28.0
Target organ damage Vascular n (%) 51 47.7
Target organ damage global 58 54.2
Arteriovenous índex 0.81 0.13
Arteriolar caliber mean (μm) 106.66 13.17
Venular caliber mean (μm) 138.55 16.80
Central Augmentation Index 27.09 13.21
Peripheral Augmentation index 90 78-102.5
ba-PWV (m/sec) 14.76 3.09
ba-PWV ≥17.5 (m/sec) 14 13.3
Cardio-Ankle Vascular Index. 8.70 1.31
Values are means and standard deviations (SD) for normally distributed
continuous data, medians and interquartile range (IQR) for asymmetrically
distributed continuous data and absolute frequency and proportions for
categorical data.
GFR: Glomerular filtration rate. MDRD-IDMS: Modification of Diet in Renal
Disease-Isotopic Dilution Mass Spectrometry. VDP: Voltage–Duration Product.
cf-PWV: carotid femoral Pulse Wave Velocity. ba-PWV: brachial ankle Pulse
Wave Velocity.
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The mean age was 61.2 ± 11.1 years (women 50.6; men
62.2), and 37.3% of the 110 subjects were women.
Table 2 shows the TOD and the parameters used to
assess the vascular structure and function. Among the
patients, 54% had one or more TOD: 10% cardiac, 13%
renal, and 48% vascular. 13% had ba-PWV ≥ 17.5 m/s. The
CAVI value was 8.71 ± 1.28 in men and 8.65 ± 1.40 in
women.
Subjects with CAVI ≥ 9 were older and had higher
values of HbA1c, office systolic blood pressure, cardiovas-
cular risk, IMT, cf-PWV, ba-PWV, and PAIx, and they had
lower values of total and LDL cholesterol (Table 3).The difference in CAVI between patients with any TOD
and patients without TOD was 1.15 (CI 95% 0.70 to 1.61,
p < 0.001). This difference was 1.14 (CI95% 0.68 to 1.60,
p < 0.001) in vascular TOD, 1.30 (CI 95% 0.51 to 2.10, p =
0.002) in the cardiac TOD, and 0.48 (CI 95% -0.27 to 1.22,
p = 0.206) in renal TOD (Figure 1).
The CAVI has a positive correlation with age (r = 0.647;
p < 0.01). The CAVI values had positive correlations
Table 3 Values of cardiovascular risk factors, organ damage markers and vascular structure and function parameters
according to CAVI value
Value of CAVI CAVI < 9 (58%) Mean/Median/SD/IQR CAVI ≥ 9 (42%) Mean/Median/SD/IQR p-value
Age (years) 56.5 ± 11.4 67.7 ± 7.3 <0.01
Waist circumference (cm) 102.9 ± 10.7 102.2 ± 12.6 0.77
Body mass index (kg/m2) 30.6 ± 4.2 29.2 ± 5.1 0.13
Total Cholesterol (mg/dL) 191.7 ± 28.1 176.6 ± 35.0 0.02
LDL cholesterol (mg/dL) 115.0 ± 28.3 102.2 ± 30.7 0.03
Tryglicerides (mg/dL) 128 (96.0-161.5) 113.5 (82.5-159.5) 0.57
HDL cholesterol (mg/dL) 50.6 ± 12.0 50.1 ± 11.5 0.85
Lipid lowering drugs n (%) 32 (52.5) 35 (79.5) <0.01
Diabetics n (%) 32 (52.5) 35 (79.5) <0.01
Serum glucose (mg/dL) 96 (85.5-120.5) 107 (93.0-130.8) 0.05
HbA1c 6.1 (5.6-6.5) 6.6 (5.9-7.1) 0.03
Antidiabetic drugs n (%) 31 (50.8) 31 (70.5) 0.05
Office SBP (mm Hg) 127 ± 14 139 ± 17 <0.01
Office DBP (mm Hg) 77 ± 9 78 ± 10 0.59
Antihypertensive Drugs n (%) 50 (82.0) 36 (81.8) 0.98
CVR Framingham D’Agostino 20.5 ± 17.1 32.0 ± 20.8 <0.01
Serum creatinine (mg/dL) 0.9 (0.8-1.0) 0.8 (0.7-1.0) 0.69
GFR with MDRD-IDMS (mL/min/1.73 m2) 92.3 ± 19.1 87.6 ± 20.0 0.22
Albumin/creatinine (mg/g) 2.97 (0.00-8.25) 2.31 (0.00-14.03) 0.93
Cornell VDP (mmms) 1548.5 ± 389.6 1661.5 ± 893.1 0.38
Sokolow (mm) 20.26 ± 5.91 19.72 ± 7.04 0.68
Ankle/brachial index 1.14 ± 0.11 1.14 ± 0.10 0.95
Carotid IMT average mean (mm) 0.74 ± 0.10 0.84 ± 0.13 <0.01
cf-PWV (m/sec) 8.63 ± 2.63 10.86 ± 2.05 <0.01
ba-PWV (m/sec) 13.18 ± 1.41 16.96 ± 3.44 <0.01
Central Augmentation Index 25.2 ± 14.8 30.0 ± 10.1 0.06
Peripheral augmentation index 90 (75–93) 92.5 (83–105) 0.04
Arteriole-venule ratio 0.73 ± 0.11 0.76 ± 0.12 0.29
CAVI: Cardio-Ankle Vascular Index. LDL: Low Density Lipoprotein. HDL: High Density Lipoprotein. HbA1C: Glycosylated Hemoglobin. SBP: Systolic Blood Pressure.
DBP: Diastolic Blood Pressure. CVR: CardioVascular Risk. GFR: Glomerular filtration rate. MDRD-IDMS: Modification of Diet in Renal Disease-Isotopic Dilution Mass
Spectrometry. VDP: Voltage–Duration Product. IMT: Intima-Media Thickness. cf-PWV: carotid femoral Pulse Wave Velocity. ba-PWV: brachial ankle Pulse
Wave Velocity.
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blood pressure (r = 0.30, and r = 0.26 p < 0.05), which
was adjusted for age, sex, and the presence of antihyper-
tensive, lipid-lowering, and antidiabetic drugs. It had a
negative correlation with waist circumference and body
mass index (r = −0.13 and r = −0.24; p < 0.05).
In the multiple regression analysis, after adjustment for
age, gender, cardiovascular risk, body mass index, and
antihypertensive, antidiabetic, and lipid-lowering drugs,
the CAVI as the independent variable showed a positive
association with IMT (β = 0.29), cf-PWV (β = 0.83),
ba-PWV (β = 2.12), CAIx (β = 3.42), and PAIx (β = 5.05)
(p < 0.05, all comparisons). We have found no correlation
between CAVI and ABI or AVR (Table 4).Discussion
The results of this study show that the CAVI is positively
associated with IMT, cf-PWV, ba-PWV, CAIx, and PAIx,
regardless of cardiovascular risk and the drug treat-
ment used. Patients with cardiovascular TOD have
higher values of CAVI. Likewise, the CAVI was posi-
tively correlated with age, HbA1c, SBP, and DBP, and it
was negatively correlated with waist circumference and
body mass index.
Similar to the data found in this work, the CAVI was
positively related with carotid IMT, cf-PWV, and ba-
PWV in type 2 diabetes mellitus patients [37]. These
results suggest that CAVI is a useful clinical marker for
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Figure 1 Mean ± SD values of CAVI in patients with and without target organ damage. a: Represents the mean values of CAVI ± SD
between patients with any TOD and those without TOD (CAVI = 9.22 ± 1.1; vs. CAVI = 8.07 ± 1.3, p < 0.01); with vascular TOD and without it (CAVI
= 9.29 ± 1.1; vs. CAVI = 8.15 ± 1.3, p = p < 0.01); with cardiac TOD and without it (CAVI = 9.86 ± 1.0; vs. CAVI = 8.56 ± 1.3, p = 0.002); and with renal
TOD and without it (CAVI = 9.11 ± 1.1; vs. CAVI = 8.63 ± 1.3, p = 0.206). b: Represents the mean values of CAVI ± SD between patients with any TOD
and those without TOD with different parameters: intima-media thickness (CAVI = 9.28 ± 1.08; vs. CAVI = 8.40 ± 1.33, p < 0.01) ; carotid femoral
pulse wave velocity (CAVI = 9.58 ± 1.12; vs. CAVI = 8.35 ± 1.22, p < 0.01); brachial ankle pulse wave velocity (CAVI = 10.53 ± 1.08; vs. CAVI = 8.41 ±
1.11, p < 0.01) and Ankle-brachial index (CAVI = 8.77 ± 1.99; vs. CAVI = 8.69 ± 1.29, (p > 0.05). c: Represents the mean values of CAVI ± SD between
patients with renal TOD and those without TOD with different parameters: glomerular filtration rate (CAVI = 9.26 ± 0.77; vs. CAVI = 8.66 ± 1.33, p > 0.05);
creatinine (CAVI = 9.15 ± 1.24; vs. CAVI = 8.65 ± 1.32, p > 0.05); albumin creatinine ratio (CAVI = 9.14 ± 0.93; vs. CAVI = 8.68 ± 1.33, p > 0.05).
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the use of CAVI as a screening tool for atherosclerosis
based on their findings from a general population study of
1014 adults showing strongly significant associations of
CAVI scores with carotid intima-media thickness. Takaki
et al. [25] compared the utility of these two parameters
to detect arterial stiffness. Both CAVI and ba-PWV
were significantly correlated with age and IMT. How-
ever, only CAVI was correlated with the parameters ofleft ventricular diastolic indices from echocardiography.
Finally, only CAVI was significantly higher in the group
with angina pectoris, and all parameters associated with
atherosclerosis suggested that CAVI is superior to ba-
PWV as a parameter of arterial stiffness.
Similarly we found an association between CAVI and
ba-PWV or cf-PWV. The extent of atherosclerosis has been
estimated using ba-PWV [6], ba-PWV are independently
associated with the presence of coronary artery calcium
Table 4 Multiple regression analysis with TOD and
vascular structure and function parameters as dependent
variables and CAVI as independent variable
Dependent variable: β CI 95% p value
IMT average mean 0.29 0.09 to 0.48 <0.01
ABI 0.02 −0.002 to 0.04 0.08
cf-PWV 0.83 0.46 to 1.19 <0.01
ba-PWV 2.12 1.76 to 2.49 <0.01
CAIx 3.42 1.12 to 5.74 <0.01
PAIx 5.05 0.19 to 9.91 0.04
AVR −0.01 −0.03 to 0.01 0.38
Dependent variable: IMT: Intima-Media Thickness of common carotid artery.
ABI: Ankle Brachial Index. cf-PWV: carotid femoral Pulse Wave Velocity. ba-PWV:
brachial ankle Pulse Wave Velocity. CAIx: Central Augmentation Index. PAIx:
Peripheral Augmentation Index. AVR: ArterioVenous Ratio.
Indepedent variable: CAVI: Cardio-Ankle Vascular Index.
Adjusted by: Framingham D’Agostino cardiovascular risk score. Body mass
index. Antihypertensive drugs. Lipid lowering drugs and antidiabetic drugs.
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but this can be influenced by blood pressure, and it is
not very reproducible. Because the CAVI is independent
of BP, highly reproducible, easy to apply, and does
not require special techniques, its potential as a novel
parameter of atherosclerosis has recently become recog-
nized [12]. Izuara et al. [38] suggested that CAVI reflects
systemic arterial sclerosis, including carotid atherosclerosis
and coronary atherosclerosis, and that CAVI might be
more useful for discriminating the probability of coronary
atherosclerosis than findings of carotid atherosclerosis by
high-resolution ba-PWV [29,46].
As far as we know, this is the first study that describes a
positive association between the CAVI, the CAIx, and
PAIx. Assessment of CAIx is a simple approach to quan-
tify the role of wave reflection in determining an elevation
of central blood pressure values [31,39]. Contrary to data
published by Masugata et al. [47], who found a relation-
ship between CAVI and the presence of left ventricule
hypertrophy, this study found no relationship with either
the left CAVI ventricule hypertrophy, renal TOD, the
thickness of arteries and veins of the retina, or the ratio
between the two.
In previous studies in Japanese population, has been
described a negative association of CAVI with estimated
glomerular filtration [48] and a positive correlation with
the albumin creatinine ratio [49,50]. In our study, probably
due to the low statistic power by the small sample size, we
found no correlation with any of these parameters.
Consistent with previous studies, we found a positive
correlation of CAVI with age, SBP, and DBP. Our study
revealed that CAVI is highly correlated with age (r = 0.65),
similar to the results reported by other authors for diabetic
subjects [51,52] and for hypertensive diabetics (r = 0.63)
[24]. A study that examined 32627 healthy residents fromJapan showed that CAVI increases almost linearly with
age from 20 to 70 years in males and females by 0.5 over
10 years [20].
The positive correlation between CAVI with SBP
and DBP remains after adjusting for age, sex, and
drug therapies used by patients. The results are con-
sistent with those reported in diabetic patients [24].
However, in hypertensive patients, a correlation has
only been found between CAVI and SBP, but not with
DBP [20,28]. Some authors such as Nakamura et al.
found no association of CAVI with blood pressure in
patients with coronary disease [46]. These discrepan-
cies suggest that the relationship of CAVI with the
different components of blood pressure could be
conditioned by previous disease presenting in the
subjects analyzed.
Consistent with published results for patients with
and without diabetes [52,53], the CAVI was positively
correlated with HbA1c (r = 0.298, p < 0.05). In summary,
these results suggest that CAVI is a good tool to detect
the presence of vascular TOD, carotid atherosclerosis,
and arterial stiffness in Caucasian patients with in-
creased insulin resistance, and they may be helpful in
clinical practice for this patient group, completing the
results published by Takata et al. in 2013 for an Asian
population [54].Limitations
The main limitation of this study was the source of the
data for the cross-sectional study, which prevented us
from establishing a temporal relationship between the
CAVI and the different FRCV, TOD, and parameters
that assess vascular function and structure during one
week. Also, at the time of viewing these results, the
subjects included in the study had multiple associated
pathologies and were being treated with many drugs,
which may have affected the CAVI values. We have
tried to control this limitation by including the drugs
most frequently used in the multiple regression analysis
and in the correlation analysis as adjustment variables.
Finally, the sample size of the individuals analyzed is
not large.Conclusions
The results of this study suggest that the CAVI is posi-
tively associated with IMT, cf-PWV, ba-PWV, CAIx,
and PAIx, regardless of cardiovascular risk and the
drug treatment used. Patients with cardiovascular
TOD have higher values of CAVI. This relationship
between CAIx, PAIx, and CAVI opens new lines of
research, since they measure different aspects of arter-
ial stiffness and could improve the treatment of car-
diovascular diseases.
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